The role of melatonin on miRNAs modulation in triple-negative breast cancer cells.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
02
2019
accepted:
07
01
2020
entrez:
4
2
2020
pubmed:
6
2
2020
medline:
25
4
2020
Statut:
epublish
Résumé
Melatonin, a hormone secreted by pineal gland, exerts antimetastatic effects by reducing tumor cell proliferation, migration and invasion. MicroRNAs (miRNAs) are small, non-coding RNAs that play a crucial role in regulation of gene expression and biological processes of the cells. Herein, we search for a link between the tumor/metastatic-suppressive actions of melatonin and miRNA expression in triple-negative breast cancer cells. We demonstrated that melatonin exerts its anti-tumor actions by reducing proliferation, migration and c-Myc expression of triple negative breast cancer cells. By using Taqman-based assays, we analyzed the expression levels of a set of miRNAs following melatonin treatment of triple negative breast cancer cells and we identified 17 differentially expressed miRNAs, 6 down-regulated and 11 up-regulated. We focused on the anti-metastatic miR-148b and the oncogenic miR-210 both up-regulated by melatonin treatment and studied the effect of their modulation on melatonin-mediated impairment of tumor progression. Surprisingly, when miR-148b or miR-210 were depleted in triple-negative breast cancer cells, using a specific miR-148b sponge or anti-miR-210, melatonin effects on migration inhibition and c-myc downregulation were still visible suggesting that the increase of miR-148b and miR-210 expression observed following melatonin treatment was not required for the efficacy of melatonin action. Nevertheless, ours results suggest that melatonin exhibit a compound for metastatic trait inhibition, especially in MDA-MB-231 breast cancer cells even if a direct link between modulation of expression of certain proteins or miRNAs and melatonin effects has still to be established.
Identifiants
pubmed: 32012171
doi: 10.1371/journal.pone.0228062
pii: PONE-D-19-04637
pmc: PMC6996834
doi:
Substances chimiques
MYC protein, human
0
MicroRNAs
0
Proto-Oncogene Proteins c-myc
0
Melatonin
JL5DK93RCL
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0228062Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Pineal Res. 2011 Oct;51(3):345-52
pubmed: 21615491
Mol Oncol. 2014 May;8(3):581-95
pubmed: 24484937
Curr Med Chem. 2010;17(36):4462-81
pubmed: 21062257
Int J Mol Sci. 2017 Apr 17;18(4):
pubmed: 28420185
Cell Cycle. 2009 Sep 1;8(17):2756-68
pubmed: 19652553
Sci Rep. 2015 Jan 28;5:8087
pubmed: 25627001
Cell. 2005 Jul 15;122(1):6-7
pubmed: 16009126
Oncol Lett. 2014 Aug;8(2):487-492
pubmed: 25009641
J Pineal Res. 2005 May;38(4):231-9
pubmed: 15813899
Mol Cancer Res. 2016 Nov;14(11):1159-1169
pubmed: 27535706
FASEB J. 2010 Oct;24(10):3603-24
pubmed: 20534884
Cancer Res. 2005 Dec 1;65(23):11174-84
pubmed: 16322268
Clin Biochem. 2015 Apr;48(6):388-96
pubmed: 25541018
Pharmacol Rev. 2010 Sep;62(3):343-80
pubmed: 20605968
Curr Neuropharmacol. 2010 Sep;8(3):194-210
pubmed: 21358970
Int J Mol Sci. 2013 Jan 24;14(2):2410-30
pubmed: 23348932
PLoS One. 2014 Dec 30;9(12):e115577
pubmed: 25549355
Breast Cancer Res Treat. 2011 May;127(1):91-8
pubmed: 20549340
Oncotarget. 2016 Apr 12;7(15):20532-48
pubmed: 26967561
Biochim Biophys Acta. 2016 Apr;1865(2):176-83
pubmed: 26899267
Cancer Res. 2016 Sep 1;76(17):5151-62
pubmed: 27328731
Anticancer Agents Med Chem. 2016;16(11):1474-1484
pubmed: 27102277
Mol Cancer. 2013 May 19;12:43
pubmed: 23683438
Cancer Metastasis Rev. 2010 Dec;29(4):785-99
pubmed: 20938719
J Pineal Res. 2010 Oct;49(3):210-21
pubmed: 20609073
Onco Targets Ther. 2016 Aug 23;9:5245-55
pubmed: 27601917
Recent Pat Endocr Metab Immune Drug Discov. 2012 May;6(2):108-16
pubmed: 22369716
J Pineal Res. 2013 Apr;54(3):264-70
pubmed: 22924616
J Intern Med. 2013 Aug;274(2):113-26
pubmed: 23844915
J Cancer. 2015 Jan 01;6(1):19-28
pubmed: 25553085
Adv Drug Deliv Rev. 2014 Dec 15;79-80:135-44
pubmed: 25453260
Integr Cancer Ther. 2009 Dec;8(4):337-46
pubmed: 20050373
Int J Mol Sci. 2015 Mar 19;16(3):6353-72
pubmed: 25809609
Oncol Lett. 2017 Aug;14(2):2511-2516
pubmed: 28781689
PLoS Genet. 2013;9(3):e1003311
pubmed: 23505378
EMBO J. 2011 May 18;30(10):1990-2007
pubmed: 21468029
Anticancer Agents Med Chem. 2016;16(3):347-58
pubmed: 25963143
J Lab Autom. 2013 Feb;18(1):30-3
pubmed: 22821877
J Pineal Res. 2016 Jan;60(1):3-15
pubmed: 26292662
Cell Mol Life Sci. 2013 Jun;70(12):2139-57
pubmed: 23007844
J Pineal Res. 2015 Mar;58(2):234-50
pubmed: 25612238
J Pineal Res. 2009 Mar;46(2):188-98
pubmed: 19054298
Adv Biol Regul. 2015 Jan;57:1-9
pubmed: 25294678
Wiley Interdiscip Rev RNA. 2014 Nov-Dec;5(6):823-33
pubmed: 25044299
J Invest Dermatol. 2015 Apr;135(4):960-969
pubmed: 25501033
Cancer Biol Ther. 2008 Feb;7(2):255-64
pubmed: 18059191